Ascendis Pharma (ASND) Q2 FY26 earnings call

Ascendis Pharma delivered a strong Q2 FY26, driven by robust uptake of its TransCon products, SKYTROFA, YORVIPATH, and the successful commercial launch of YUVIWEL. The company is advancing its pipeline, including combination therapies and new chemical entities, while navigating an ongoing patent dispute for YUVIWEL. Management remains confident in achieving its Vision 2030 objectives, supported by its differentiated technology platform and global commercial infrastructure.